Home › Paraproteinemias › NCT01408225
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion: Diagnosis of a plasma cell dyscrasia Exclusion: Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.
About the study
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:
* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
What is being tested
- tissue banking (procedure)
Sponsor: Ohio State University Comprehensive Cancer Center · Participants: 5,000 · Started: Mar 17, 2011
Contact the study team
- The Ohio State University Comprehensive Cancer Center · Phone: 1-800-293-5066
Official record on ClinicalTrials.gov — NCT01408225
Locations in the U.S.
| Ohio | Ohio State University Medical Center, Columbus |
Conditions
- Paraproteinemias
- Monoclonal Gammopathy of Undetermined Significance
- Immunoglobulin Light-chain Amyloidosis
- Multiple Myeloma
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.